Location of Repository

Transdermal buprenorphine in the management of persistent pain – safety aspects

By Rudolf Likar


By virtue of their efficacy, opioid analgesics have long been used for the treatment of both acute and chronic pain. Concerns regarding their safety and tolerability have frequently prevented this class of drugs achieving their full therapeutic potential, and their reported association with drug abuse and dependence has led to a reduced acceptance by many patients. Indeed, there is a variety of opioid-like side effects which are common to all members of the class, but some opioids have a more favourable safety profile than others. Buprenorphine is a semisynthestic opioid with a μ-agonistic and κ-antagonistic receptor-binding profile. Studies over the past two decades have shown buprenorphine to have a complex and unique pharmacological profile, which results in enhanced therapeutic benefits combined with a favourable safety profile. Having been underused before, the development of a new transdermal drug delivery system for buprenorphine has revived interest in this substance. Transdermal buprenorphine (Gruenenthal GmbH, Aachen, Germany) provides a noninvasive method of rate-controlled drug release ensuring constant and predictable serum buprenorphine levels over a prolonged period. This preparation has been shown to be advantageous for long-term treatment of chronic pain patients providing reliable pain control, few adverse events, and good patient acceptance

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:1661652
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (1980). A classification of opiate receptors that mediate antinociception in animals.
    2. (1988). A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther,
    3. (1982). A comparison of the effects of buprenorphine and morphine on the blood gases of conscious rats.
    4. (2005). A comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans rats.
    5. (1978). A double-blind comparison of morphine and buprenorphine in the prevention of pain after operation.
    6. (2001). A double-blind, placebocontrolled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency.
    7. (2004). Acute pain, the immune system and opioidimmunosuppression. Acute Pain,
    8. (1986). An open study of sub-lingual buprenorphine in the treatment of chronic pain in the elderly. Curr Med Res Opin,
    9. (2003). Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial.
    10. (1994). Assessment of immunotoxicity of buprenorphine. Lab Anim,
    11. (2002). Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction.
    12. (1991). Buprenorphine and sustained release morphine – effect and side-effects in chronic use. The Pain Clinic,
    13. (1990). Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites.
    14. (1985). Buprenorphine in end stage renal failure.
    15. (1988). Buprenorphine is a potent k-opioid receptor antagonist in pigeons and mice.
    16. (1995). Buprenorphine kinetics in humans. In: Cowan A, Lewis JW (eds). Buprenorphine combating drug abuse with a unique opioid.
    17. (1980). Buprenorphine kinetics. Clin Pharmacol Ther,
    18. (1986). Buprenorphine kinetics. In: Advances in pain research and therapy. Vol 8.
    19. (2003). Buprenorphine TDS: use in daily practice, benefits for patients.
    20. (2003). Buprenorphine-induced antinociception is mediated by µ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.
    21. (1979). Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.
    22. (2002). Buprenorphine: a review. In: Evidence based medicine in practice.
    23. (2002). Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction.
    24. (1996). Cancer pain relief: with a guide to opioid availability. 2nd Ed.
    25. (1995). Caudal analgesia with buprenorphine for postoperative pain relief in children. Paedriatr Anaesth,
    26. (2005). Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and non-cancer pain in Germany result of a retrospective cohort study. Clin Ther,
    27. (2004). Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses.
    28. (1985). Clinical actions of fentanyl and buprenorphine: the significance of receptor binding.
    29. (1994). Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther,
    30. (1995). Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.
    31. (1988). Comparison of buprenorphine with morphine in the treatment of postoperative pain of children.
    32. (2005). Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model.
    33. (1996). Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.
    34. (1998). Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain.
    35. (2006). Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine.
    36. (2005). Efficacy and safety of a buprenorphine-transdermal patch with 4 days’ wearing time compared with the current application period of 3 days – a randomized cross-over study.
    37. (2005). Efficacy and safety of transdermal buprenorphine 70µg/h in patients suffering from severe chronic cancer pain. A randomized, placebo-controlled, double-blind multicentre study [abstract,
    38. (2003). Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomized, doubleblind, placebo-controlled study. The Pain Clinic,
    39. (2005). Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and non-cancer pain: results of a prospective cohort study. Clin Ther,
    40. (2000). Excessive CNS depression due to the combination of buprenorphine and benzodiazepines is most likely due to additive or synergistic pharmacologic effects unrelated to a pharmacokinetic interaction between the drugs.
    41. High dose buprenorphine for postoperative analgesia.
    42. (1978). Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry,
    43. (2002). Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.
    44. (2003). Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos,
    45. (2005). Interaction of µ-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
    46. (1997). Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice.
    47. (2000). Ligand induced changes in surface µ-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther,
    48. (1979). Methodology of monitored release of a new preparation: buprenorphine.
    49. (1989). Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther,
    50. (2003). Old dog –new (ma)trix.
    51. (2004). Opioids and renal function.
    52. (1995). Paediatric ventilatory effects of morphine and buprenorphine revisited. Paediatr Anaesth,
    53. (1994). Pharmacokinetic characterization of transdermal delivery systems.
    54. (1996). Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet,
    55. (1994). Renal failure: effects on morphine and buprenorphine kinetics in
    56. (1999). Signal transduction in neuropathic pain, with special emphasis on the analgesic role of opioids – Part II: Moving basic science towards a new pharmacology. Pain Rev,
    57. (2003). The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend, 70(Suppl 2):S13–27.
    58. (1976). The effects of morphineand nalorphine- like drugs in the nondependent and morphinedependent chronic spinal dog.
    59. (1990). The efficacy in sequential use of buprenorphine and morphine in advanced cancer pain. In: Doyle D (ed). Opioids in the treatment of cancer pain.
    60. (2004). the Opioid Study Group of the Spanish Pain Society,
    61. (2004). the Opioid Study Group of the Spanish Pain Society.
    62. (1999). Therapy with opioids in liver or renal failure.
    63. (2005). Transdermal buprenorphine for longterm management of chronic cancer and non-cancer pain. Results of an open-label, multicentre, follow-up study.
    64. (2003). Transdermal buprenorphine for the treatment of chronic cancer and noncancer pain (article in German). Wien Med Woschr,
    65. (2005). Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg,
    66. (2005). Transdermal buprenorphine in clinical practice – a post-marketing surveillance study in 13,179 patients.
    67. (2001). Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients.
    68. (2004). Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases.
    69. (1995). Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.